Novo Nordisk's $1.1 Billion Sickle Cell Bet Cleared Its Phase 3 Test. The Hard Part Is Still Coming.

Novo Nordisk says its experimental sickle cell pill works well enough to win regulatory approval. The data just were not what the company was hoping for.

The Danish pharma giant announced Monday that etavopivat, a daily oral drug acquired in a $1.1 billion deal in 2022, cleared the Phase 3 HIBISCUS trial — the confirmatory study needed for FDA filing. But the results came in below internal expectations, according to a report by Endpoints News, leaving the drug's commercial prospects uncertain as the sickle cell market confronts an unusual competitive dynamic: curative gene therapies that cost more than $2 million per patient.

The numbers themselves have not been published. Novo Nordisk has not issued a press release with the full dataset, and the company did not respond to a request for comment by publication time. What is known is that etavopivat targets pyruvate kinase-R — an enzyme that modulates red blood cell metabolism — with the goal of preventing the vaso-occlusive crises, severe pain episodes, that define sickle cell disease. Phase 2 data, presented at the American Society of Hematology meeting in late 2024, showed a trend toward fewer crises over 52 weeks and higher hemoglobin levels at 24 weeks compared to placebo, establishing proof of concept, according to PR Newswire.

The Phase 3 HIBISCUS trial enrolled roughly 380 patients randomized to 400 milligrams of etavopivat or placebo, per the trial registry on ClinicalTrials.gov. Novo's own SEC filings, dated before the readout, described the Phase 3 segment as ongoing with an expected 2026 data release — consistent with Monday's announcement.

The competitive context is what makes this interesting beyond a routine Phase 3 readout. Vertex Pharmaceuticals and CRISPR Therapeutics won FDA approval for Casgevy in December 2023, pricing it at $2.2 million per patient. Bluebird bio followed with Lyfgenia at $3.1 million, according to BioPharma Dive. Both are one-time gene therapies, while etavopivat would require continuous daily dosing — a recurring revenue model that looks very different at a fraction of the upfront price.

Novo acquired the drug from Forma Therapeutics in 2022, paying $1.1 billion to establish itself as a player in sickle cell, according to FierceBiotech. Whether etavopivat can actually compete on value rather than just list price depends entirely on how large its treatment benefit turns out to be. A pill that reduces crisis frequency modestly at low cost has a plausible argument to make to insurers exhausted by gene therapy list prices. A pill that barely moves the needle is a tough sell against a potential cure, regardless of price.

The full Phase 3 dataset has not been released. When it is, the comparison that matters is not just etavopivat versus placebo, but etavopivat versus a $2 million alternative that, for some patients, might be worth it.